ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.

Chunfang HuJiyan Dong Li LiuJingbo LiuXujie SunFei TengXin WangJianming YingJunling LiPu-Yuan Xing Lin Yang

Published in: Thoracic cancer (2021)

ASCL1 and DLL3 were highly expressed in SCLC tumor samples, and a positive correlation between these two markers was observed. Co-analysis of ASCL1 and DLL3 may identify a distinct SCLC subgroup benefit from targeted therapy. Therefore, ASCL1 and DLL3 could be potential biomarkers served for the selection of related patients.

Keyphrases

small cell lung cancer
end stage renal disease
prognostic factors
ejection fraction
newly diagnosed
randomized controlled trial
patient reported outcomes
study protocol
brain metastases
patient reported
double blind